Mr. Louis Laflamme reports

HAEMONETICS COMPLETES ACQUISITION OF OPSENS

Opsens Inc. has successfully completed the previously announced acquisition by Haemonetics Corp. of all of the issued and outstanding common shares in the capital of Opsens for $2.90 in cash per share, pursuant to a statutory plan of arrangement under the Business Corporations Act (Quebec).

Consideration for the purchased shares has been remitted to TSX Trust Company, as depositary under the arrangement, and will be paid to former shareholders of Opsens as soon as reasonably practicable after the date hereof (or, in the case of registered shareholders, as soon as reasonably practicable after a properly completed and signed letter of transmittal is received by the depositary together with the share certificate(s) or DRS (direct registration system) advice(s) representing shares formerly held by them, if applicable).

As a result of the completion of the arrangement, it is expected that trading of the shares will cease in the public market, and the shares will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX Best Market designation, in each case, shortly after the date hereof. The corporation will also apply to cease to be a reporting issuer under Canadian securities laws.

Registered shareholders of the corporation are reminded to submit a properly completed and signed letter of transmittal, together with all required documents, including the share certificate(s) and/or DRS advice(s) representing shares formerly held by them, as applicable, to TSX Trust Company. Registered shareholders must submit such properly completed and signed letter of transmittal, together with all required documents, to TSX Trust Company in order to receive the consideration to which they are entitled for their shares. Non-registered shareholders of the corporation should carefully follow the instructions from the broker, investment dealer, bank, trust company, custodian, nominee or other intermediary that holds shares on their behalf in order to ensure they receive the consideration to which they are entitled for their shares.

About Opsens Inc.

Opsens focuses mainly on cardiology. The corporation offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fibre optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of more than 250,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan and Canada.

Opsens has received U.S. Food and Drug Administration clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a three-in-one solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.

Opsens's SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to leave the hospital earlier, sometimes the same day. The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is expected to reach over 400,000 in 2025 and over 600,000 in 2030.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

We seek Safe Harbor.